Systemic Sclerosis
Systemic sclerosis, commonly known as scleroderma, is a rare autoimmune disease that causes the skin and connective tissues to harden and tighten, potentially affecting internal organs.
Systemic Sclerosis: Anifrolumab Treatment Study
We are investigating whether Anifrolumab can improve symptoms and lung function in adults with systemic sclerosis. This study compares the new treatment to a placebo to see how well it works.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Immune System Diseases
Immune system diseases occur when the body's immune system mistakenly attacks healthy cells, leading to various health issues.
Interstitial Lung Disease
Interstitial lung disease (ILD) refers to a group of disorders that cause scarring of the lung tissue, leading to breathing difficulties.
Autoimmune Diseases
Autoimmune diseases occur when the immune system attacks the body's own tissues, leading to inflammation and damage.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 70 years old?
- Are you currently pregnant or breastfeeding?
- Have you had any major surgery in the past 8 weeks?
- Do you have a known history of cancer in the last 5 years?
- Is your body weight 145 kg (319.7 lb) or less?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Anifrolumab
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical University Of Graz
Department of Rheumatology and Immunology
Graz, Austria
Medizinische Universitaet Innsbruck
Department of Internal Medicine
Innsbruck, Austria
Ordensklinikum Linz GmbH
Dermatology
Linz, Austria
Sponsor: Astrazeneca AB
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.